Silenor, a low-dose doxepin oral tablet formulation, is developed to treat insomnia and symptoms such as frequent nocturnal awakening and/or early morning awakenings. Somaxon president and chief executive
The termination of one of three Phase 3 rheumatoid arthritis registration studies of the anti-BAFF monoclonal antibody is not due to safety concerns and patients presently enrolled in
The deal allows Genmab, which received €7.5m upfront payment previously, to develop human antibodies against three central nervous system targets identified by Lundbeck. Lundbeck, which will entirely fund
MM-141, the company’s sixth oncology candidate that advanced into clinical development, is developed to target P13K/AKT/mTOR pathway that is believed to play a vital role in tumor cell
AAV1-FS344 is myostatin inhibitor delivered through gene therapy to increase muscle strength in patients. At present the company is conducting a Phase I/II trial in patients with Becker
XEN402 is designed to treat pain by targeting sodium channels located at sensory nerve endings. Teva Pharmaceutical Industries president and CEO Dr. Jeremy Levin said, "XEN402 fits this
Griseofulvin tablets are antifungal antibiotics which are used to treat ringworm infections of the skin, hair, and nails. Previously, the company has also launched the first generic version
Patients with intermediate-2 or high-risk primary or secondary MF were involed in open label, randomised dose-ranging study that assessed the once-daily oral doses of 300mg, 400mg, and 500mg
Paracetamol is an over the counter analgesic drug. The company has submitted the product to the FDB labs for testing and is yet to receive final approval, which
The collaboration will make use of Amorfix’s ProMIS discovery technology and the terms of the deal are kept confidential. Amorfix president and CEO Dr. Robert Gundel said, "This
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.